PE20091680A1 - Cristal de compuestos de bencimidazol - Google Patents

Cristal de compuestos de bencimidazol

Info

Publication number
PE20091680A1
PE20091680A1 PE2009000341A PE2009000341A PE20091680A1 PE 20091680 A1 PE20091680 A1 PE 20091680A1 PE 2009000341 A PE2009000341 A PE 2009000341A PE 2009000341 A PE2009000341 A PE 2009000341A PE 20091680 A1 PE20091680 A1 PE 20091680A1
Authority
PE
Peru
Prior art keywords
crystal
benzhimidazole
compounds
methyl
trifluoroetoxy
Prior art date
Application number
PE2009000341A
Other languages
English (en)
Inventor
Hideo Hashimoto
Tadashi Urai
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40577894&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091680(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PE20091680A1 publication Critical patent/PE20091680A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Abstract

REFERIDO A UN CRISTAL DE (R)-2-[[[3-METIL-4-(2,2,2-TRIFLUOROETOXI)-2-PIRIDINIL]METIL]SULFINIL]-1H-BENCIMIDAZOL, DONDE EL PATRON DE ANALISIS DE DIFRACCION DE RAYOS X DE POLVO TIENE PICOS CARACTERISTICOS EN ESPACIOS INTERPLANOS (d)DE 10,06 ±0,2, 8,70 ±0,2, 6,57 ±0,2, 5,59 ±0,2 Y 4,00 ±0,2 ANGSTROM. SE REFIERE TAMBIEN A UN METODO DE PREPARACION Y UNA COMPOSICION FARMACEUTICA. DICHAS FORMAS CRISTALINAS SON UTILES EN EL TRATAMIENTO DE LA ULCERA PEPTICA, SINDROME DE ZOLLINGER-ELLISON, GASTRITIS, ENTRE OTROS
PE2009000341A 2008-03-10 2009-03-09 Cristal de compuestos de bencimidazol PE20091680A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008059342 2008-03-10

Publications (1)

Publication Number Publication Date
PE20091680A1 true PE20091680A1 (es) 2009-11-16

Family

ID=40577894

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000341A PE20091680A1 (es) 2008-03-10 2009-03-09 Cristal de compuestos de bencimidazol

Country Status (30)

Country Link
US (1) US8222422B2 (es)
EP (1) EP2262790B1 (es)
JP (3) JP2011513202A (es)
KR (1) KR20100123758A (es)
CN (1) CN102026994B (es)
AR (1) AR070972A1 (es)
AU (1) AU2009224247B2 (es)
BR (1) BRPI0909651A2 (es)
CA (1) CA2671369C (es)
CL (1) CL2009000547A1 (es)
CO (1) CO6300956A2 (es)
CR (1) CR11707A (es)
DO (1) DOP2010000274A (es)
EA (1) EA017064B1 (es)
EC (1) ECSP10010531A (es)
ES (1) ES2638463T3 (es)
GE (1) GEP20125649B (es)
IL (1) IL207867A0 (es)
LT (1) LT2262790T (es)
MA (1) MA32215B1 (es)
MX (1) MX2010009641A (es)
MY (1) MY150833A (es)
NZ (1) NZ588379A (es)
PE (1) PE20091680A1 (es)
PT (1) PT2262790T (es)
TW (1) TWI447110B (es)
UA (1) UA103189C2 (es)
UY (1) UY31695A (es)
WO (1) WO2009113696A1 (es)
ZA (1) ZA201006754B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011004387A2 (en) 2009-06-18 2011-01-13 Matrix Laboratories Ltd Process for the preparation of dexlansoprazole polymorphic forms
CN102108077B (zh) * 2009-12-23 2013-09-25 江苏豪森医药集团有限公司 制备右兰索拉唑的方法
WO2011092665A1 (en) * 2010-01-29 2011-08-04 Ranbaxy Laboratories Limited Process for the preparation of crystalline forms of dexlansoprazole
CN104447695A (zh) * 2013-11-22 2015-03-25 广东东阳光药业有限公司 一种苯并咪唑化合物的水合物
RU2672248C1 (ru) 2015-06-08 2018-11-13 СиДжей ХЕЛТКЕР КОРПОРЕЙШН Применение производного бензимидазола для лечения ночного кислотного прорыва
MA46973A (fr) * 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Polymorphes de sépiaptérine et leurs sels
CN106866631A (zh) * 2017-04-06 2017-06-20 山东裕欣药业有限公司 一种右旋兰索拉唑晶型及制备方法
CN111491635A (zh) 2017-09-01 2020-08-04 显莎制药公司 包含墨蝶呤的药物组合物及其用途
KR20210014662A (ko) * 2018-05-25 2021-02-09 이마라 인크. 6-[(3S,4S)-4-메틸-1-(피리미딘-2-일메틸)피롤리딘-3-일]-3-테트라히드로피란-4-일-7H-이미다조[1,5-a]피라진-8-온의 일수화물 및 결정형
US11365170B2 (en) 2018-07-13 2022-06-21 Kyowa Hakko Bio Co., Ltd. Non-solvate crystal of eucomic acid and method for producing same
CN113376273B (zh) * 2021-06-02 2023-03-17 国药集团精方（安徽）药业股份有限公司 一种清心莲子饮hplc特征图谱的检测方法及该特征图谱的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
DK171989B1 (da) 1987-08-04 1997-09-08 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af 2-(2-pyridylmethylsulfinyl)-benzimidazoler
DE4035455A1 (de) 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
SE504459C2 (sv) 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
GB9423968D0 (en) 1994-11-28 1995-01-11 Astra Ab Resolution
HRP960232A2 (en) 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
TW385306B (en) * 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
TR199901101T2 (xx) 1996-11-22 1999-07-21 The Procter & Gamble Company Gastroenstentinal hastal�klar�n tedavisine y�nelik bizmut ve nsaid i�eren bile�imler.
SE510666C2 (sv) 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
DE59801792D1 (de) * 1997-08-08 2001-11-22 Aventis Pharma Gmbh Kristallform von N-(4-Trifluormethylphenyl)-5-methylisoxazol-4-carbonsäureamid
AU742620B2 (en) 1998-01-30 2002-01-10 Sepracor, Inc. R-lansoprazole compositions and methods
JP2002501896A (ja) 1998-01-30 2002-01-22 セプラコール， インク． Ｓ−ランソプラゾール組成物及び方法
EP1075267A2 (en) 1998-05-06 2001-02-14 Kobenhavns Universitet Treatment of celiac disease
JP3283252B2 (ja) * 1999-06-17 2002-05-20 武田薬品工業株式会社 ベンズイミダゾール化合物の結晶
TWI275587B (en) 1999-06-17 2007-03-11 Takeda Chemical Industries Ltd A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
JP3374314B2 (ja) * 2000-05-15 2003-02-04 武田薬品工業株式会社 結晶の製造法
ES2521690T3 (es) * 2000-05-15 2014-11-13 Takeda Pharmaceutical Company Limited Procedimiento para producir un cristal de (R)-2-[[[3-metil-4-(2,2,2-trifluoroetoxi)-2-piridil]metil]sulfinil]-bencimidazol
JP4327424B2 (ja) * 2000-05-15 2009-09-09 武田薬品工業株式会社 結晶の製造法
PT1337525E (pt) * 2000-12-01 2011-09-01 Takeda Pharmaceutical Processo para a cristalização de (r)- ou (s)-lansoprazole
JP4160293B2 (ja) * 2000-12-01 2008-10-01 武田薬品工業株式会社 結晶の製造法
JP4749660B2 (ja) * 2002-10-16 2011-08-17 武田薬品工業株式会社 安定な固形製剤
CA2771725C (en) * 2002-10-16 2015-08-18 Takeda Pharmaceutical Company Limited Solid preparation comprising a non-toxic base and a proton pump inhibitor
EP2573082A1 (en) 2007-12-31 2013-03-27 Takeda Pharmaceutical Company Limited Crystalline solvated forms of (r)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1h-benzimidazole

Also Published As

Publication number Publication date
TW200938531A (en) 2009-09-16
US8222422B2 (en) 2012-07-17
EP2262790A1 (en) 2010-12-22
MY150833A (en) 2014-02-28
AU2009224247A1 (en) 2009-09-17
CO6300956A2 (es) 2011-07-21
CL2009000547A1 (es) 2010-05-07
PT2262790T (pt) 2017-07-18
EA017064B1 (ru) 2012-09-28
EP2262790B1 (en) 2017-06-07
JP2015163623A (ja) 2015-09-10
ECSP10010531A (es) 2010-11-30
JP2014015477A (ja) 2014-01-30
CN102026994B (zh) 2014-05-07
DOP2010000274A (es) 2010-09-30
AU2009224247A2 (en) 2010-10-28
BRPI0909651A2 (pt) 2015-09-22
CR11707A (es) 2010-11-04
ES2638463T3 (es) 2017-10-20
UA103189C2 (ru) 2013-09-25
EA201071053A1 (ru) 2011-04-29
GEP20125649B (en) 2012-09-25
JP2011513202A (ja) 2011-04-28
KR20100123758A (ko) 2010-11-24
MX2010009641A (es) 2010-09-22
UY31695A (es) 2009-11-10
TWI447110B (zh) 2014-08-01
US20110046183A1 (en) 2011-02-24
IL207867A0 (en) 2010-12-30
MA32215B1 (fr) 2011-04-01
LT2262790T (lt) 2017-08-25
AU2009224247B2 (en) 2013-12-12
CA2671369C (en) 2011-05-10
NZ588379A (en) 2012-07-27
AR070972A1 (es) 2010-05-19
ZA201006754B (en) 2011-11-30
CN102026994A (zh) 2011-04-20
WO2009113696A1 (en) 2009-09-17
CA2671369A1 (en) 2009-09-10

Similar Documents

Publication Publication Date Title
PE20091680A1 (es) Cristal de compuestos de bencimidazol
BRPI0620081B8 (pt) composto e composição farmacêutica.
CY1117434T1 (el) Φαρμακευτικες μορφες απιξαμπανης
AR031069A1 (es) Cristal de un compuesto benzimidazol, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima
ATE512969T1 (de) Benzimidazolderivate als selektive säurepumpenhemmer
ATE442140T1 (de) Chroman-substituierte benzimidazolderivate als säurepumpenantagonisten
NO20085121L (no) Benzimidazolderivater, deres fremstillingsmate, deres anvendelse som FXR-agonister og farmasoytiske blandinger inneholdende samme
ATE433980T1 (de) Gyraseinhibitoren und deren verwendungen
CY1108742T1 (el) Κρυσταλλικη μορφη της μηλεϊνικης ασεναπινης
DE602006019090D1 (de) Pulverförmige kalkzusammensetzung, herstellungsverfahren dafür und verwendung davon
NO20076294L (no) Fremgangsmåte for å redusere nitrogenoksidkonsentrasjonen i gasser
HRP20050604A2 (en) Process for preparing optically pure active compounds
CY1110034T1 (el) Παραγωγα 1,2,4,5-τετραϋδρο-3h-βενζαζεπινων, μεθοδος παρασκευης αυτων και οι φαρμακευτικες συνθεσεις που τα περιεχουν
NO20092049L (no) Nye fenylsulfamoylbenzamidderivater som bradykininantagonister
ATE484501T1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole
CY1111367T1 (el) Νεα παραγωγα της διοσμετινης, η μεθοδος παρασκευης τους και οι φαρμακευτικες συνθεσεις που τα περιεχουν
EA200800374A1 (ru) 1,4-дигидропиридин-конденсированные гетероциклы, способы их получения, применение и содержащие их композиции
RS53138B (en) 4- [2- (4-METHYLPHENYLSULPHANYL) PHENYL] PIPERIDINE FOR THE TREATMENT OF INJURED INTENTION SYNDROME (IBS).
WO2008076092A3 (en) Semiconductor device and method for forming the same
NO20085317L (no) Imidazoazepinonforbindelser
NO20092655L (no) 2-kinolinon- og 2-kinoksalinonderivater og deres anvendelse som antibakterielle midler
CY1111432T1 (el) Τετραϋδροκινολινες για χρηση ως διαμορφωτες της μιτοτικης κινητικης πρωτεϊνης eg5
FR2881742B1 (fr) Pyrroles substitues, compositions les contenant, procede de fabrication et utilisation
DE60213802D1 (de) Cak inhibitoren und deren verwendungen
CY1110944T1 (el) Νεα παραγωγα κυκλοαλκυλιωμενων βενζοθειαδιαζινων, μεθοδος παρασκευης αυτων και οι φαρμακευτικες συνθεσεις που τα περιεχουν

Legal Events

Date Code Title Description
FC Refusal